|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6280 EUR | +2.61% |
|
+8.96% | -59.64% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 11/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 56.34M | |
| 37.49x | 6.08x | -0.7x | 5.32x | 20.75x | 27.55x | 2.66% | 316B | |
| 24.07x | 2.04x | -17.46x | 3.29x | 11.68x | 19.35x | 1.64% | 71.26B | |
| 12.33x | 12.96x | 0.08x | 6.27x | 9.55x | 10.49x | - | 9.76B | |
| 16.27x | 1.41x | 0.79x | 2.05x | 6.96x | 8.41x | 2.78% | 8.4B | |
| 20.91x | 5.55x | 2.1x | 5.9x | 16.72x | 17.42x | -.--% | 4.29B | |
| 36.91x | 2.38x | -1.59x | 2.29x | 27.81x | 41.33x | 0.76% | 3.83B | |
| 30.03x | - | 0.19x | 5.73x | 16.37x | 26.53x | - | 3.5B | |
| 95.83x | - | -0.56x | - | - | - | -.--% | 2.68B | |
| 62.05x | - | -0.12x | - | - | - | - | 1.24B | |
| 14.04x | 0.81x | -0.82x | 1.12x | 8.14x | 27.82x | 4.41% | 1.02B | |
| -68.5x | 1.66x | 1.03x | - | - | - | - | 923M | |
| Average | 25.58x | 4.11x | -1.55x | 4.00x | 14.75x | 22.36x | 1.75% | 35.21B | |
| Weighted average by Cap. | 34.14x | 5.39x | -3.45x | 4.90x | 18.62x | 25.39x | 2.42% |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
